-
1
-
-
0037065502
-
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
-
Antithrombotic Trialists' Collaboration
-
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324,71-86 (2002).
-
(2002)
BMJ
, vol.324
, pp. 71-86
-
-
-
2
-
-
85013973898
-
-
Michelson, A. D. (ed.) 2nd edn (Elsevier/ Academic Press, San Diego
-
Michelson, A. D. (ed.) Platelets 2nd edn (Elsevier/ Academic Press, San Diego, 2007).
-
(2007)
Platelets
-
-
-
3
-
-
42649128355
-
Platelets and wound healing
-
Nurden, A. T., Nurden, P., Sanchez, M., Andia, I. & Anitua, E. Platelets and wound healing. Front. Biosci. 13, 3532-3548 (2008).
-
(2008)
Front. Biosci.
, vol.13
, pp. 3532-3548
-
-
Nurden, A.T.1
Nurden, P.2
Sanchez, M.3
Andia, I.4
Anitua, E.5
-
4
-
-
2942546273
-
Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization
-
Furman, M. I. et al. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J. Am. Coll. Cardiol. 43, 2319-2325 (2004).
-
(2004)
J. Am. Coll. Cardiol.
, vol.43
, pp. 2319-2325
-
-
Furman, M.I.1
-
5
-
-
57349102283
-
12 receptor-induced activation and kinocidin release
-
12 receptor-induced activation and kinocidin release. Infect. Immun. 76, 5706-5713 (2008).
-
(2008)
Infect. Immun.
, vol.76
, pp. 5706-5713
-
-
Trier, D.A.1
-
6
-
-
38949178835
-
Angiogenesis is regulated by a novel mechanism: Pro-and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released
-
Italiano, J. E. Jr et al. Angiogenesis is regulated by a novel mechanism: pro-and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 111, 1227-1233 (2008).
-
(2008)
Blood
, vol.111
, pp. 1227-1233
-
-
Italiano Jr., J.E.1
-
7
-
-
75949129616
-
-
2nd edn (ed. Michelson, A. D.) (Elsevier/Academic Press, San Diego
-
Nierodzik, M. L., Karpatkin, S. in Platelets 2nd edn (ed. Michelson, A. D.) 769-778 (Elsevier/Academic Press, San Diego, 2007).
-
(2007)
Platelets
, pp. 769-778
-
-
Nierodzik, M.L.1
Karpatkin, S.2
-
8
-
-
84884754706
-
-
2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
-
White, J. G. in Platelets 2nd edn (ed. Michelson, A. D.) 45-73 (Elsevier/Academic Press, San Diego, 2007).
-
(2007)
Platelets
, pp. 45-73
-
-
White, J.G.1
-
9
-
-
84884795579
-
-
2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
-
Italiano, J. E. & Hartwig, J. H. in Platelets 2nd edn (ed. Michelson, A. D.) 23-44 (Elsevier/Academic Press, San Diego, 2007).
-
(2007)
Platelets
, pp. 23-44
-
-
Italiano, J.E.1
Hartwig, J.H.2
Levin, J.3
-
10
-
-
85013973898
-
-
2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
-
Levin, J. in Platelets 2nd edn (ed. Michelson, A. D.) 3-22 (Elsevier/Academic Press, San Diego, 2007).
-
(2007)
Platelets
, pp. 3-22
-
-
-
11
-
-
84884789064
-
-
Elsevier/ Academic Press, San Diego
-
Clemetson, K. J. & Clemetson, J. M. in Platelets 2nd edn (ed. Michelson, A. D.) 117-143 (Elsevier/ Academic Press, San Diego, 2007).
-
(2007)
Platelets 2nd Edn (Ed. Michelson, A. D.)
, pp. 117-143
-
-
Clemetson, K.J.1
Clemetson, J.M.2
-
12
-
-
61849117080
-
-
2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
-
Hartwig, J. H. in Platelets 2nd edn (ed. Michelson, A. D.) 75-97 (Elsevier/Academic Press, San Diego, 2007).
-
(2007)
Platelets
, pp. 75-97
-
-
Hartwig, J.H.1
-
13
-
-
67649753929
-
-
2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
-
Rex, S. & Freedman, J. E. in Platelets 2nd edn (ed. Michelson, A. D.) 251-279 (Elsevier/Academic Press, San Diego, 2007).
-
(2007)
Platelets
, pp. 251-279
-
-
Rex, S.1
Freedman, J.E.2
-
14
-
-
84884808691
-
-
2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
-
Brass, L. F., Stalker, T. J., Zhu, L. & Woulfe, D. S. in Platelets 2nd edn (ed. Michelson, A. D.) 319-346 (Elsevier/Academic Press, San Diego, 2007).
-
(2007)
Platelets
, pp. 319-346
-
-
Brass, L.F.1
Stalker, T.J.2
Zhu, L.3
Woulfe, D.S.4
-
15
-
-
0001299961
-
Acetylation of prostaglandin synthase by aspirin
-
Roth, G. J., Stanford, N. & Majerus, P. W. Acetylation of prostaglandin synthase by aspirin. Proc. Natl Acad. Sci. USA 72, 3073-3076 (1975).
-
(1975)
Proc. Natl Acad. Sci. USA
, vol.72
, pp. 3073-3076
-
-
Roth, G.J.1
Stanford, N.2
Majerus, P.W.3
-
16
-
-
0029056992
-
The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase
-
Loll, P. J., Picot, D. & Garavito, R. M. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nature Struct. Biol. 2, 637-643 (1995).
-
(1995)
Nature Struct. Biol.
, vol.2
, pp. 637-643
-
-
Loll, P.J.1
Picot, D.2
Garavito, R.M.3
-
17
-
-
46049108934
-
Antiplatelet drugs
-
American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)
-
Patrono, C., Baigent, C., Hirsh, J. & Roth, G. Antiplatelet drugs. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133, S199-S233 (2008).
-
(2008)
Chest
, vol.133
-
-
Patrono, C.1
Baigent, C.2
Hirsh, J.3
Roth, G.4
-
18
-
-
56749160744
-
Lack of association between cyclooxygenase-1-dependent platelet function assays and adverse clinical outcomes in 700 consecutive aspirin-treated patients presenting for cardiac catheterization
-
Frelinger, A. L. et al. Lack of association between cyclooxygenase-1- dependent platelet function assays and adverse clinical outcomes in 700 consecutive aspirin-treated patients presenting for cardiac catheterization. J. Am. Coll. Cardiol. 51, A370 (2008).
-
(2008)
J. Am. Coll. Cardiol.
, vol.51
-
-
Frelinger, A.L.1
-
20
-
-
34447503098
-
-
Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis
-
Snoep, J. D., Hovens, M. M., Eikenboom, J. C., van der Bom, J. G. & Huisman, M. V. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch. Intern. Med. 167, 1593-1599 (2007).
-
(2007)
Arch. Intern. Med.
, vol.167
, pp. 1593-1599
-
-
Snoep, J.D.1
Hovens, M.M.2
Eikenboom, J.C.3
Van Der Bom, J.G.4
Huisman, M.V.5
-
21
-
-
38949119325
-
Aspirin "resistance" and risk of cardiovascular morbidity: Systematic review and meta-analysis
-
Krasopoulos, G., Brister, S. J., Beattie, W. S. & Buchanan, M. R. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336, 195-203 (2008).
-
(2008)
BMJ
, vol.336
, pp. 195-203
-
-
Krasopoulos, G.1
Brister, S.J.2
Beattie, W.S.3
Buchanan, M.R.4
-
22
-
-
56749182302
-
Aspirin 'resistance': Role of pre-existent platelet reactivity and correlation between tests
-
Frelinger, A. L. et al. Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. J. Thromb.Haemost. 6, 2035-2044 (2008).
-
(2008)
J. Thromb.Haemost.
, vol.6
, pp. 2035-2044
-
-
Frelinger, A.L.1
-
23
-
-
84884759628
-
-
2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
-
Cattaneo, M. in Platelets 2nd edn (ed. Michelson, A. D.) 201-220 (Elsevier/Academic Press, San Diego, 2007).
-
(2007)
Platelets
, pp. 201-220
-
-
Cattaneo, M.1
-
24
-
-
84884782925
-
-
2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
-
Cattaneo, M. in Platelets 2nd edn (ed. Michelson, A. D.) 1127-1144 (Elsevier/Academic Press, San Diego, 2007).
-
(2007)
Platelets
, pp. 1127-1144
-
-
Cattaneo, M.1
-
25
-
-
40749148947
-
12 antagonism: Promises and challenges. Arterioscler
-
12 antagonism: promises and challenges. Arterioscler. Thromb. Vasc. Biol. 28, S33-S38 (2008).
-
(2008)
Thromb. Vasc. Biol.
, vol.28
-
-
Michelson, A.D.1
-
26
-
-
0034622539
-
Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS)
-
Bertrand, M. E., Rupprecht, H. J., Urban, P. & Gershlick, A. H. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102, 624-629 (2000).
-
(2000)
Circulation
, vol.102
, pp. 624-629
-
-
Bertrand, M.E.1
Rupprecht, H.J.2
Urban, P.3
Gershlick, A.H.4
-
27
-
-
0035899289
-
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
-
Yusuf, S. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494-502 (2001).
-
(2001)
N. Engl. J. Med.
, vol.345
, pp. 494-502
-
-
Yusuf, S.1
-
28
-
-
0035908781
-
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study
-
Mehta, S. R. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358, 527-533 (2001).
-
(2001)
Lancet
, vol.358
, pp. 527-533
-
-
Mehta, S.R.1
-
29
-
-
0037145863
-
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial
-
Steinhubl, S. R. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288, 2411-2420 (2002).
-
(2002)
JAMA
, vol.288
, pp. 2411-2420
-
-
Steinhubl, S.R.1
-
30
-
-
27644548513
-
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial
-
Chen, Z. M. et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366, 1607-1621 (2005).
-
(2005)
Lancet
, vol.366
, pp. 1607-1621
-
-
Chen, Z.M.1
-
31
-
-
20144373281
-
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
-
Sabatine, M. S. et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. 352, 1179-1189 (2005).
-
(2005)
N. Engl. J. Med.
, vol.352
, pp. 1179-1189
-
-
Sabatine, M.S.1
-
32
-
-
33645861080
-
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
-
Bhatt, D. L. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354,1706-1717 (2006).
-
(2006)
N. Engl. J. Med.
, vol.354
, pp. 1706-1717
-
-
Bhatt, D.L.1
-
33
-
-
34548809256
-
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial
-
Wang, T. H. et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur. Heart J. 28, 2200-2207 (2007).
-
(2007)
Eur. Heart J.
, vol.28
, pp. 2200-2207
-
-
Wang, T.H.1
-
34
-
-
34447576539
-
Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis
-
Snoep, J. D. et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am. Heart J. 154, 221-231 (2007).
-
(2007)
Am. Heart J.
, vol.154
, pp. 221-231
-
-
Snoep, J.D.1
-
35
-
-
8344221349
-
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction
-
Matetzky, S. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109, 3171-3175 (2004).
-
(2004)
Circulation
, vol.109
, pp. 3171-3175
-
-
Matetzky, S.1
-
36
-
-
27644465874
-
Clopidogrel effect on platelet reactivity in patients with stent thrombosis. Results of the CREST study
-
Gurbel, P. A. et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis. Results of the CREST study. J. Am. Coll. Cardiol. 46, 1827-1832 (2005).
-
(2005)
J. Am. Coll. Cardiol.
, vol.46
, pp. 1827-1832
-
-
Gurbel, P.A.1
-
37
-
-
33645982865
-
High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome
-
Cuisset, T. et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J. Thromb. Haemost. 4, 542-549 (2006).
-
(2006)
J. Thromb. Haemost.
, vol.4
, pp. 542-549
-
-
Cuisset, T.1
-
38
-
-
33750479499
-
Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement
-
Hochholzer, W. et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J. Am. Coll. Cardiol. 48, 1742-1750 (2006).
-
(2006)
J. Am. Coll. Cardiol.
, vol.48
, pp. 1742-1750
-
-
Hochholzer, W.1
-
39
-
-
33846837282
-
Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate?
-
Bliden, K. P. et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J. Am. Coll. Cardiol. 49, 657-666 (2007).
-
(2007)
J. Am. Coll. Cardiol.
, vol.49
, pp. 657-666
-
-
Bliden, K.P.1
-
40
-
-
34250020766
-
Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis
-
Buonamici, P. et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 49, 2312-2317 (2007).
-
(2007)
J. Am. Coll. Cardiol.
, vol.49
, pp. 2312-2317
-
-
Buonamici, P.1
-
41
-
-
60949083948
-
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis
-
Sibbing, D. et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 53, 849-856 (2009).
-
(2009)
J. Am. Coll. Cardiol.
, vol.53
, pp. 849-856
-
-
Sibbing, D.1
-
42
-
-
59849120163
-
Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: A 12-month follow-up
-
Marcucci, R. et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 11 9, 237-242 (2009).
-
(2009)
Circulation
, vol.11
, Issue.9
, pp. 237-242
-
-
Marcucci, R.1
-
43
-
-
34447636769
-
Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events
-
Bonello, L. et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J. Thromb. Haemost. 5, 1630-1636 (2007).
-
(2007)
J. Thromb. Haemost.
, vol.5
, pp. 1630-1636
-
-
Bonello, L.1
-
44
-
-
41249093357
-
Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance. A multicenter randomized prospective study
-
Bonello, L. et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance. A multicenter randomized prospective study. J. Am. Coll. Cardiol. 51, 1404-1411 (2008).
-
(2008)
J. Am. Coll. Cardiol.
, vol.51
, pp. 1404-1411
-
-
Bonello, L.1
-
45
-
-
34047096264
-
Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives
-
Angiolillo, D. J. et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol. 49, 1505-1516 (2007).
-
(2007)
J. Am. Coll. Cardiol.
, vol.49
, pp. 1505-1516
-
-
Angiolillo, D.J.1
-
46
-
-
57649084454
-
Impact of "nuisance"bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation
-
Roy, P. et al. Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am. J. Cardiol. 102, 1614-1617 (2008).
-
(2008)
Am. J. Cardiol.
, vol.102
, pp. 1614-1617
-
-
Roy, P.1
-
47
-
-
56849095254
-
Initiation and persistence with clopidogrel treatment after acute myocardial infarction: A nationwide study
-
Sorensen, R. et al. Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study. Brit. J. Clin. Pharmacol. 66, 875-884 (2008).
-
(2008)
Brit. J. Clin. Pharmacol.
, vol.66
, pp. 875-884
-
-
Sorensen, R.1
-
48
-
-
38349065084
-
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study
-
Gilard, M. et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J. Am. Coll. Cardiol. 51, 256-260 (2008).
-
(2008)
J. Am. Coll. Cardiol.
, vol.51
, pp. 256-260
-
-
Gilard, M.1
-
49
-
-
61549124132
-
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome
-
Ho, P. M. et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301, 937-944 (2009).
-
(2009)
JAMA
, vol.301
, pp. 937-944
-
-
Ho, P.M.1
-
50
-
-
57149104093
-
Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel
-
Siller-Matula, J. M. et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am. Heart J. 157, 148.e1-148.e5 (2009).
-
(2009)
Am. Heart J.
, vol.157
-
-
Siller-Matula, J.M.1
-
51
-
-
64849087438
-
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel
-
Sibbing, D. et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb. Haemost. 101, 714-719 (2009).
-
(2009)
Thromb. Haemost.
, vol.101
, pp. 714-719
-
-
Sibbing, D.1
-
52
-
-
70249139788
-
Pharmacodynamic and clinical efficacy of clopidogrel and of prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials
-
O'Donoghue, M. L. et al. Pharmacodynamic and clinical efficacy of clopidogrel and of prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 374, 989-997 (2009).
-
(2009)
Lancet
, vol.374
, pp. 989-997
-
-
O'Donoghue, M.L.1
-
53
-
-
48449101872
-
The association of cigarette smoking with enhanced platelet inhibition by clopidogrel
-
Bliden, K. P. et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J. Am. Coll. Cardiol. 52, 531-533 (2008).
-
(2008)
J. Am. Coll. Cardiol.
, vol.52
, pp. 531-533
-
-
Bliden, K.P.1
-
54
-
-
63549115843
-
Interaction between cigarette smoking and clinical benefit of clopidogrel
-
Desai, N. R., Mega, J. L., Jiang, S., Cannon, C. P. & Sabatine, M. S. Interaction between cigarette smoking and clinical benefit of clopidogrel. J. Am. Coll. Cardiol. 53, 1273-1278 (2009).
-
(2009)
J. Am. Coll. Cardiol.
, vol.53
, pp. 1273-1278
-
-
Desai, N.R.1
Mega, J.L.2
Jiang, S.3
Cannon, C.P.4
Sabatine, M.S.5
-
55
-
-
58749094444
-
Cytochrome p-450 polymorphisms and response to clopidogrel
-
Mega, J. L. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354-362 (2009).
-
(2009)
N. Engl. J. Med.
, vol.360
, pp. 354-362
-
-
Mega, J.L.1
-
56
-
-
58749090547
-
Genetic determinants of response to clopidogrel and cardiovascular events
-
Simon, T. et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363-375 (2009).
-
(2009)
N. Engl. J. Med.
, vol.360
, pp. 363-375
-
-
Simon, T.1
-
57
-
-
58249135635
-
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study
-
Collet, J. P. et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373, 309-317 (2009).
-
(2009)
Lancet
, vol.373
, pp. 309-317
-
-
Collet, J.P.1
-
58
-
-
33845528397
-
Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'
-
Michelson, A. D. et al. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'. J. Thromb. Haemost. 5, 75-81 (2007).
-
(2007)
J. Thromb. Haemost.
, vol.5
, pp. 75-81
-
-
Michelson, A.D.1
-
59
-
-
9644281092
-
Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting
-
Angiolillo, D. J. et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb. Res. 11 5, 101-108 (2005).
-
(2005)
Thromb. Res.
, vol.11
, Issue.5
, pp. 101-108
-
-
Angiolillo, D.J.1
-
60
-
-
7544239072
-
High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability
-
Angiolillo, D. J. et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur. Heart J. 25, 1903-1910 (2004).
-
(2004)
Eur. Heart J.
, vol.25
, pp. 1903-1910
-
-
Angiolillo, D.J.1
-
61
-
-
9644281093
-
The difference between clopidogrel responsiveness and posttreatment platelet reactivity
-
Samara, W. M., Bliden, K. P., Tantry, U. S. & Gurbel, P. A. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb. Res. 11 5, 89-94 (2005).
-
(2005)
Thromb. Res.
, vol.11
, Issue.5
, pp. 89-94
-
-
Samara, W.M.1
Bliden, K.P.2
Tantry, U.S.3
Gurbel, P.A.4
-
62
-
-
0038649988
-
Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity
-
Gurbel, P. A., Bliden, K. P., Hiatt, B. L. & O'Connor, C. M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107, 2908-2913 (2003).
-
(2003)
Circulation
, vol.107
, pp. 2908-2913
-
-
Gurbel, P.A.1
Bliden, K.P.2
Hiatt, B.L.3
O'Connor, C.M.4
-
63
-
-
23644433510
-
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment
-
Angiolillo, D. J. et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54, 2430-2435 (2005).
-
(2005)
Diabetes
, vol.54
, pp. 2430-2435
-
-
Angiolillo, D.J.1
-
64
-
-
34347242071
-
Thrombosis and drug-eluting stents: An objective appraisal
-
Holmes, D. R. Jr et al. Thrombosis and drug-eluting stents: an objective appraisal. J. Am. Coll. Cardiol. 50,109-118 (2007).
-
(2007)
J. Am. Coll. Cardiol.
, vol.50
, pp. 109-118
-
-
Holmes Jr., D.R.1
-
65
-
-
36849074168
-
Prasugrel:a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile
-
Jakubowski, J. A., Winters, K. J., Naganuma, H. & Wallentin, L. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovas Drug Rev. 25, 357-374 (2007).
-
(2007)
Cardiovas Drug Rev.
, vol.25
, pp. 357-374
-
-
Jakubowski, J.A.1
Winters, K.J.2
Naganuma, H.3
Wallentin, L.4
-
66
-
-
34250714831
-
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite
-
Sugidachi, A. et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J. Thromb. Haemost. 5, 1545-1551(2007).
-
(2007)
J. Thromb. Haemost.
, vol.5
, pp. 1545-1551
-
-
Sugidachi, A.1
-
67
-
-
33845451677
-
A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation
-
Brandt, J. T. et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am. Heart J. 153, 66 (2007).
-
(2007)
Am. Heart J.
, vol.153
, pp. 66
-
-
Brandt, J.T.1
-
68
-
-
33646732608
-
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
-
Jernberg, T. et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur. Heart J. 27, 1166-1173 (2006).
-
(2006)
Eur. Heart J.
, vol.27
, pp. 1166-1173
-
-
Jernberg, T.1
-
69
-
-
36348977461
-
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel
-
Payne, C. D. et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J. Cardiovasc. Pharmacol. 50, 555-562 (2007).
-
(2007)
J. Cardiovasc. Pharmacol.
, vol.50
, pp. 555-562
-
-
Payne, C.D.1
-
70
-
-
37349111065
-
Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial
-
Wiviott, S. D. et al. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 11 6, 2923-2932 (2007).
-
(2007)
Circulation
, vol.11
, Issue.6
, pp. 2923-2932
-
-
Wiviott, S.D.1
-
71
-
-
67651173161
-
Pharmacodynamic assessment of platelet inhibition by prasugrel versus clopidogrel in the TRITON-TIMI 38 trial
-
Michelson, A. D. et al. Pharmacodynamic assessment of platelet inhibition by prasugrel versus clopidogrel in the TRITON-TIMI 38 trial. Eur. Heart, J. 30, 1753-1763 (2009).
-
(2009)
Eur. Heart J.
, vol.30
, pp. 1753-1763
-
-
Michelson, A.D.1
-
72
-
-
36148983750
-
Prasugrel versus clopidogrel in patients with acute coronary syndromes
-
Wiviott, S. D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007).
-
(2007)
N. Engl. J. Med.
, vol.357
, pp. 2001-2015
-
-
Wiviott, S.D.1
-
73
-
-
60649112469
-
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomised controlled trial
-
Montalescot, G. et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373, 723-731 (2009).
-
(2009)
Lancet
, vol.373
, pp. 723-731
-
-
Montalescot, G.1
-
74
-
-
55949103494
-
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38
-
Wiviott, S. D. et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 11 8, 1626-1636 (2008).
-
(2008)
Circulation
, vol.11
, Issue.8
, pp. 1626-1636
-
-
Wiviott, S.D.1
-
75
-
-
18044388905
-
Preclinical and clinical studies with selective reversible direct P2Y12 antagonists
-
van Giezen, J. J. & Humphries, R. G. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin. Thromb. Hemost. 31, 195-204 (2005).
-
(2005)
Semin. Thromb. Hemost.
, vol.31
, pp. 195-204
-
-
Van Giezen, J.J.1
Humphries, R.G.2
-
76
-
-
33646261670
-
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin
-
Husted, S. et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur. Heart J. 27,1038-1047 (2006).
-
(2006)
Eur. Heart J.
, vol.27
, pp. 1038-1047
-
-
Husted, S.1
-
77
-
-
35548995394
-
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: Primary results of the DISPERSE-2 trial
-
erratum 50, 2196 2007
-
Cannon, C. P. et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J. Am. Coll. Cardiol. 50,1844-1851 (2007); erratum 50, 2196 (2007).
-
(2007)
J. Am. Coll. Cardiol.
, vol.50
, pp. 1844-1851
-
-
Cannon, C.P.1
-
78
-
-
35548933800
-
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes
-
Storey, R. F. et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 50,1852-1856 (2007).
-
(2007)
J. Am. Coll. Cardiol.
, vol.50
, pp. 1852-1856
-
-
Storey, R.F.1
-
79
-
-
70149101223
-
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
-
Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045-1057 (2009).
-
(2009)
N. Engl. J. Med.
, vol.361
, pp. 1045-1057
-
-
Wallentin, L.1
-
80
-
-
0035085132
-
Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes
-
Storey, R. F., Oldroyd, K. G. & Wilcox, R. G. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb. Haemost. 85, 401-407 (2001).
-
(2001)
Thromb. Haemost.
, vol.85
, pp. 401-407
-
-
Storey, R.F.1
Oldroyd, K.G.2
Wilcox, R.G.3
-
81
-
-
33344464928
-
Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo-and active-controlled trial
-
Greenbaum, A. B. et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo-and active-controlled trial. Am. Heart J. 151, 689 (2006).
-
(2006)
Am. Heart J.
, vol.151
, pp. 689
-
-
Greenbaum, A.B.1
-
82
-
-
47649127254
-
12 inhibitor for IV and oral use
-
12 inhibitor for IV and oral use. J. Am. Coll. Cardiol. 49 (suppl. 2), 326A (2007).
-
(2007)
J. Am. Coll. Cardiol.
, vol.49
, Issue.SUPPL.2
-
-
Gretler, D.D.1
-
84
-
-
43149088638
-
-
2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
-
Agah, R., Plow, E. F. & Topol, E. J. in Platelets 2nd edn (ed. Michelson, A. D.) 1145-1163 (Elsevier/Academic Press, San Diego, (2007).
-
(2007)
Platelets
, pp. 1145-1163
-
-
Agah, R.1
Plow, E.F.2
Topol, E.J.3
-
85
-
-
0016246099
-
An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia
-
Nurden, A. T. & Caen, J. P. An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia. Br. J. Haematol. 28, 253-260 (1974).
-
(1974)
Br. J. Haematol.
, vol.28
, pp. 253-260
-
-
Nurden, A.T.1
Caen, J.P.2
-
86
-
-
0030999134
-
Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics
-
Coller, B. S. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J. Clin. Invest. 99, 1467-1471 (1997).
-
(1997)
J. Clin. Invest.
, vol.99
, pp. 1467-1471
-
-
Coller, B.S.1
-
87
-
-
0031041549
-
In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time
-
Ammar, T., Scudder, L. E. & Coller, B. S. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 95, 614-617 (1997).
-
(1997)
Circulation
, vol.95
, pp. 614-617
-
-
Ammar, T.1
Scudder, L.E.2
Coller, B.S.3
-
88
-
-
0029914728
-
Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis"
-
Reverter, J. C. et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J. Clin. Invest. 98, 863-874 (1996).
-
(1996)
J. Clin. Invest.
, vol.98
, pp. 863-874
-
-
Reverter, J.C.1
-
89
-
-
0033828457
-
GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidyl serine expression in whole blood
-
Furman, M. I. et al. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidyl serine expression in whole blood. Thromb. Haemost. 84, 492-498 (2000).
-
(2000)
Thromb. Haemost.
, vol.84
, pp. 492-498
-
-
Furman, M.I.1
-
90
-
-
0030870212
-
F Networking in the hemostatic system. Integrin alphaIIb beta3 binds prothrombin and influences its activation
-
Byzova, T. V. & Plow, E. F Networking in the hemostatic system. Integrin alphaIIb beta3 binds prothrombin and influences its activation. J. Biol. Chem. 272, 27183-27188 (1997).
-
(1997)
J. Biol. Chem.
, vol.272
, pp. 27183-27188
-
-
Byzova, T.V.1
Plow, E.2
-
91
-
-
41849101706
-
Glycoprotein IIb/IIIa receptor inhibitors in 2008: Do they still have a role?
-
Mukherjee, D. & Roffi, M. Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role? J. Interv. Cardiol. 21, 118-121 (2008).
-
(2008)
J. Interv. Cardiol.
, vol.21
, pp. 118-121
-
-
Mukherjee, D.1
Roffi, M.2
-
92
-
-
0035895332
-
Increased mortality with oral platelet glycoprotein IIb/ IIIa antagonists: A meta-analysis of phase III multicenter randomized trials
-
Chew, D. P., Bhatt, D. L, Sapp, S. & Topol, E. J. Increased mortality with oral platelet glycoprotein IIb/ IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 103, 201-206 (2001).
-
(2001)
Circulation
, vol.103
, pp. 201-206
-
-
Chew, D.P.1
Bhatt, D.L.2
Sapp, S.3
Topol, E.J.4
-
93
-
-
0025873010
-
"Activate"integrin alpha IIb beta 3 (platelet GPIIb-IIIa)
-
Du, X. P. et al. Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa). Cell 65, 409-416 (1991).
-
(1991)
Cell
, vol.65
, pp. 409-416
-
-
Du, X.P.1
Ligands, E.2
-
94
-
-
38949130475
-
Application of high-throughput screening to identify a novel a-specific small-molecule inhibitor of aIIb|33-mediated platelet interaction with fibrinogen
-
Blue, R., Murcia, M., Karan, C, Jirouskova, M. & Coller, B. S. Application of high-throughput screening to identify a novel a-specific small-molecule inhibitor of aIIb|33-mediated platelet interaction with fibrinogen. Blood 111, 1248-1256 (2008).
-
(2008)
Blood
, vol.111
, pp. 1248-1256
-
-
Blue, R.1
Murcia, M.2
Karan, C.3
Jirouskova, M.4
Coller, B.S.5
-
95
-
-
59849117765
-
Antiaggregatory and proangiogenic effects of a novel recombinant human dual specificity anti-integrin antibody
-
Escher, R. et al. Antiaggregatory and proangiogenic effects of a novel recombinant human dual specificity anti-integrin antibody. J. Thromb. Haemost. 7, 460-469 (2009).
-
(2009)
J. Thromb. Haemost.
, vol.7
, pp. 460-469
-
-
Escher, R.1
-
96
-
-
34247402058
-
Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation
-
Stoll, P. et al. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation. Arterioscler. Thromb. Vasc. Biol. 27, 1206-1212 (2007).
-
(2007)
Arterioscler. Thromb. Vasc. Biol.
, vol.27
, pp. 1206-1212
-
-
Stoll, P.1
-
97
-
-
84884771147
-
-
2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
-
Eisert, W. G. in Platelets 2nd edn (ed. Michelson, A. D.) 1165-1179 (Elsevier/Academic Press, San Diego, 2007).
-
(2007)
Platelets
, pp. 1165-1179
-
-
Eisert, W.G.1
-
98
-
-
0030297319
-
European Stroke Prevention Study.2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
-
Diener, H. C. et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143, 1-13 (1996).
-
(1996)
J. Neurol. Sci.
, vol.143
, pp. 1-13
-
-
Diener, H.C.1
-
99
-
-
33646596912
-
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial
-
ESPRIT Study Group et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367, 1665-1673 (2006).
-
(2006)
Lancet
, vol.367
, pp. 1665-1673
-
-
Study Group, E.1
-
100
-
-
51449116270
-
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke
-
Sacco, R. L. et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N. Engl. J. Med. 359, 1238-1251 (2008).
-
(2008)
N. Engl. J. Med.
, vol.359
, pp. 1238-1251
-
-
Sacco, R.L.1
-
101
-
-
70449501536
-
-
Elsevier/Academic Press, San Diego
-
Ikeda, Y., Sudo, T. & Kimura, Y in Platelets 2nd edn (ed. Michelson, A. D.) 1181-1191 (Elsevier/Academic Press, San Diego, 2007).
-
(2007)
Platelets 2nd Edn (Ed. Michelson A. D.)
, pp. 1181-1191
-
-
Ikeda, Y.1
Sudo, T.2
Kimura, Y.3
-
102
-
-
44349138210
-
Systematic review and metaanalysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention
-
Biondi-Zoccai, G. G. et al. Systematic review and metaanalysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am. Heart J. 155,1081-1089 (2008).
-
(2008)
Am. Heart J.
, vol.155
, pp. 1081-1089
-
-
Biondi-Zoccai, G.G.1
-
103
-
-
34548633702
-
Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial)
-
Lee, S. W. et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am. J. Cardiol. 100,1103-1108 (2007).
-
(2007)
Am. J. Cardiol.
, vol.100
, pp. 1103-1108
-
-
Lee, S.W.1
-
104
-
-
52449085759
-
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: Results of the OPTIMUS-2 study
-
Angiolillo, D. J. et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur. Heart J. 29, 2202-2211 (2008).
-
(2008)
Eur. Heart J.
, vol.29
, pp. 2202-2211
-
-
Angiolillo, D.J.1
-
106
-
-
61849180442
-
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: A randomised, double-blind, placebo-controlled phase II study
-
Becker, R. C. et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 373, 919-928 (2009).
-
(2009)
Lancet
, vol.373
, pp. 919-928
-
-
Becker, R.C.1
-
107
-
-
36448941387
-
Inhibitory effect of E5555, an orally active thrombin receptor antagonist, on intimal hyperplasia following balloon injury
-
Matsuoka, T. et al. Inhibitory effect of E5555, an orally active thrombin receptor antagonist, on intimal hyperplasia following balloon injury. J. Am. Coll. Cardiol. 43, 68A (2004).
-
(2004)
J. Am. Coll. Cardiol.
, vol.43
-
-
Matsuoka, T.1
-
108
-
-
49849103616
-
-
Hsu, C. C., Wu, W. B. & Huang, T. F. A snake venom metalloproteinase, kistomin, cleaves platelet glycoprotein VI and impairs platelet functions. J. Thromb. Haemost. 6, 1578-1585 (2008).
-
(2008)
A Snake Venom Metalloproteinase, Kistomin, Cleaves Platelet Glycoprotein VI and Impairs Platelet Functions. J. Thromb. Haemost.
, vol.6
, pp. 1578-1585
-
-
Hsu, C.C.1
Wu, W.B.2
Huang, T.F.3
-
109
-
-
43049116482
-
A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex
-
Takayama, H. et al. A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex. J. Clin. Invest. 11 8, 1785-1795 (2008).
-
(2008)
J. Clin. Invest.
, vol.11
, Issue.8
, pp. 1785-1795
-
-
Takayama, H.1
-
110
-
-
58849165421
-
Small-molecule inhibitors of integrin α2β1 that prevent pathological thrombus formation via an allosteric mechanism
-
Miller, M. W. et al. Small-molecule inhibitors of integrin α2β1 that prevent pathological thrombus formation via an allosteric mechanism. Proc. Natl Acad. Sci. USA 106, 719-724 (2009).
-
(2009)
Proc. Natl Acad. Sci. USA
, vol.106
, pp. 719-724
-
-
Miller, M.W.1
-
111
-
-
69249236278
-
2A receptor improves coronary patency in an in vivo model of recurrent thrombosis
-
2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. Circulation 116, II-206 (2007).
-
(2007)
Circulation
, vol.116
-
-
Przyklenk, K.1
-
112
-
-
0032951722
-
In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX-4016
-
Wallace, J. L. et al. In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX-4016. Thromb. Res. 93, 43-50 (1999).
-
(1999)
Thromb. Res.
, vol.93
, pp. 43-50
-
-
Wallace, J.L.1
-
113
-
-
34247121053
-
Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG
-
Lorusso, R. et al. Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG. Int. J. Cardiol. 11 8, 164-169 (2007).
-
(2007)
Int. J. Cardiol.
, vol.11
, Issue.8
, pp. 164-169
-
-
Lorusso, R.1
-
114
-
-
54949095069
-
The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons
-
Fontayne, A. et al. The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Thromb. Haemost. 100, 670-677 (2008).
-
(2008)
Thromb. Haemost.
, vol.100
, pp. 670-677
-
-
Fontayne, A.1
-
115
-
-
12444303861
-
Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin
-
Falati, S. et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J. Exp Med. 197, 1585-1598 (2003).
-
(2003)
J. Exp Med.
, vol.197
, pp. 1585-1598
-
-
Falati, S.1
-
116
-
-
0033574172
-
Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model
-
Kumar, A. et al. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. Circulation 99,1363-1369 (1999).
-
(1999)
Circulation
, vol.99
, pp. 1363-1369
-
-
Kumar, A.1
-
117
-
-
38749140235
-
Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7, 8, 9, 10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis
-
Bedard, P. W. et al. Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8, 9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis. J. Pharmacol. Exp. Ther. 324, 497-506 (2008).
-
(2008)
J. Pharmacol. Exp. Ther.
, vol.324
, pp. 497-506
-
-
Bedard, P.W.1
-
118
-
-
38949147126
-
Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation
-
Meier, T. R. et al. Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation. Thromb. Haemost. 99, 343-351 (2008).
-
(2008)
Thromb. Haemost.
, vol.99
, pp. 343-351
-
-
Meier, T.R.1
-
119
-
-
0023543565
-
Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism
-
of proaggregatory and antiaggregatory prostaglandins in hemostasis
-
Gresele, P. et al. of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J. Clin. Invest. 80,1435-1445 (1987).
-
(1987)
J. Clin. Invest.
, vol.80
, pp. 1435-1445
-
-
Gresele, P.1
-
120
-
-
0025020113
-
Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers
-
Fiddler, G. I. & Lumley, P. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review. Circulation 81 (Suppl. 1), 78 (1990).
-
(1990)
A Review. Circulation
, vol.81
, Issue.SUPPL.1
, pp. 78
-
-
Fiddler, G.I.1
Lumley, P.2
-
121
-
-
6944234992
-
Antithrombotic effects of S18886, a novel orally active thromboxane A2 receptor antagonist
-
Osende, J. I., Shimbo, D., Fuster, V., Dubar, M. & Badimon, J. J. Antithrombotic effects of S18886, a novel orally active thromboxane A2 receptor antagonist. J. Thromb. Haemost. 2, 492-498 (2004).
-
(2004)
J. Thromb. Haemost.
, vol.2
, pp. 492-498
-
-
Osende, J.I.1
Shimbo, D.2
Fuster, V.3
Dubar, M.4
Badimon, J.J.5
-
122
-
-
0037414069
-
Improved endothelial function by the thromboxane A2 receptor antagonist S18886 in patients with coronary artery disease treated with aspirin
-
Belhassen, L., Pelle, G., Dubois-Rande, J. L. & Adnot, S. Improved endothelial function by the thromboxane A2 receptor antagonist S18886 in patients with coronary artery disease treated with aspirin. J. Am. Coll. Cardiol. 41, 1198-1204 (2003).
-
(2003)
J. Am. Coll. Cardiol.
, vol.41
, pp. 1198-1204
-
-
Belhassen, L.1
Pelle, G.2
Dubois-Rande, J.L.3
Adnot, S.4
-
123
-
-
25144437017
-
The specific thromboxane receptor antagonist S18886: Pharmacokinetic and pharmacodynamic studies
-
Gaussem, P. et al. The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. J. Thromb. Haemost. 3, 1437-1445 (2005).
-
(2005)
J. Thromb. Haemost.
, vol.3
, pp. 1437-1445
-
-
Gaussem, P.1
-
124
-
-
33845927424
-
Distinct effects of z-335, a new thromboxane A2 receptor antagonist, on rabbit platelets and aortic smooth muscle
-
Yoshida, M. et al. Distinct effects of z-335, a new thromboxane A2 receptor antagonist, on rabbit platelets and aortic smooth muscle. Pharmacology 79, 50-56 (2007).
-
(2007)
Pharmacology
, vol.79
, pp. 50-56
-
-
Yoshida, M.1
-
125
-
-
0344737009
-
The thromboxane receptor antagonist PBT-3, a hepoxilin stable analog, selectively antagonizes the TPα isoform in transfected COS-7 cells
-
Qiao, N. et al. The thromboxane receptor antagonist PBT-3, a hepoxilin stable analog, selectively antagonizes the TPα isoform in transfected COS-7 cells. J. Pharmacol. Exp. Ther. 307, 1142-1147 (2003).
-
(2003)
J. Pharmacol. Exp. Ther.
, vol.307
, pp. 1142-1147
-
-
Qiao, N.1
-
126
-
-
0025203077
-
Cardioprotective actions of the specific thromboxane receptor antagonist (+)-S145Na following coronary occlusion and reperfusion in the rat. Res
-
Tsao, P. S. & Lefer, A. M. Cardioprotective actions of the specific thromboxane receptor antagonist (+)-S145Na following coronary occlusion and reperfusion in the rat. Res. Commun. Chem. Pathol. Pharmacol. 70, 205-211 (1990).
-
(1990)
Commun. Chem. Pathol. Pharmacol.
, vol.70
, pp. 205-211
-
-
Tsao, P.S.1
Lefer, A.M.2
-
127
-
-
0042386436
-
Effects of selective cyclooxygenase inhibitors on ischemia/reperfusion- induced hepatic microcirculatory dysfunction in mice
-
Ito, Y. et al. Effects of selective cyclooxygenase inhibitors on ischemia/reperfusion-induced hepatic microcirculatory dysfunction in mice. Eur. Sur. Res. 35, 408-416 (2003).
-
(2003)
Eur. Sur. Res.
, vol.35
, pp. 408-416
-
-
Ito, Y.1
-
128
-
-
0005556702
-
Augmented contraction of the human isolated coronary artery by sumatriptan: A possible role for endogenous thromboxane
-
Maassen, V. A. et al. Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane. Br. J. Pharmacol. 11 9, 855-862 (1996).
-
(1996)
Br. J. Pharmacol.
, vol.11
, Issue.9
, pp. 855-862
-
-
Maassen, V.A.1
-
129
-
-
0030611110
-
Thromboxane A2 receptor density increases during chronic exposure to thromboxane A2 receptor antagonists after porcine carotid bypass
-
Brothers, T. E., Robison, J. G., Elliott, B. M., Boggs, J. M. & Halushka, P. V. Thromboxane A2 receptor density increases during chronic exposure to thromboxane A2 receptor antagonists after porcine carotid bypass. Cardiovasc. Surg. 5, 92-98 (1997).
-
(1997)
Cardiovasc. Surg.
, vol.5
, pp. 92-98
-
-
Brothers, T.E.1
Robison, J.G.2
Elliott, B.M.3
Boggs, J.M.4
Halushka, P.V.5
-
130
-
-
4944241267
-
Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics (DAVID) Study Group. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: The DAVID study
-
Neri Serneri, G. G., Coccheri, S., Marubini, E. & Violi, F. Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics (DAVID) Study Group. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur. Heart J. 25,1845-1852 (2004).
-
(2004)
Eur. Heart J
, vol.25
, pp. 1845-1852
-
-
Neri Serneri, G.G.1
Coccheri, S.2
Marubini, E.3
Violi, F.4
-
131
-
-
12244289930
-
Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function
-
Dogne, J. M. et al. Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function. Prostaglandins Leukot. Essent. Fatty Acids 68, 49-54 (2003).
-
(2003)
Prostaglandins Leukot. Essent. Fatty Acids
, vol.68
, pp. 49-54
-
-
Dogne, J.M.1
-
132
-
-
33644537934
-
Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion
-
Kolh, P. et al. Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion. Prostaglandins Other Lipid Mediat. 79, 53-73 (2006).
-
(2006)
Prostaglandins Other Lipid Mediat
, vol.79
, pp. 53-73
-
-
Kolh, P.1
-
133
-
-
0028851697
-
Antiaggregating and vasodilatory effects of a new nitroderivative of acetylsalicylic acid
-
Minuz, P. et al. Antiaggregating and vasodilatory effects of a new nitroderivative of acetylsalicylic acid. Thromb. Res. 80, 367-376 (1995).
-
(1995)
Thromb. Res.
, vol.80
, pp. 367-376
-
-
Minuz, P.1
-
134
-
-
65249093133
-
2 are novel antiplatelet agents that do not prolong bleeding
-
2 are novel antiplatelet agents that do not prolong bleeding. ACS Chem. Biol. 4, 115-126 (2009).
-
(2009)
ACS Chem. Biol.
, vol.4
, pp. 115-126
-
-
Singh, J.1
-
135
-
-
0036098158
-
Essential role for phosphoinositide 3-kinase in shear-dependent signaling between platelet glycoprotein Ib/V/IX and integrin αiIbβ3
-
Yap, C. L. et al. Essential role for phosphoinositide 3-kinase in shear-dependent signaling between platelet glycoprotein Ib/V/IX and integrin αIIbβ3. Blood 99,151-158 (2002).
-
(2002)
Blood
, vol.99
, pp. 151-158
-
-
Yap, C.L.1
-
136
-
-
44149087073
-
Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat
-
Sturgeon, S. A., Jones, C., Angus, J. A. & Wright, C. E. Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat. Eur. J. Pharmacol. 587, 209-215 (2008).
-
(2008)
Eur. J. Pharmacol.
, vol.587
, pp. 209-215
-
-
Sturgeon, S.A.1
Jones, C.2
Angus, J.A.3
Wright, C.E.4
-
137
-
-
42949101432
-
Discovery-based strategies for studying platelet function
-
Flaumenhaft, R. & Dilks, J. R. Discovery-based strategies for studying platelet function. Mini Rev. Med. Chem. 8, 350-357 (2008).
-
(2008)
Mini Rev. Med. Chem.
, vol.8
, pp. 350-357
-
-
Flaumenhaft, R.1
Dilks, J.R.2
-
138
-
-
67651056213
-
Platelet membrane proteomics: A novel repository for functional research
-
Lewandrowski, U. et al. Platelet membrane proteomics: a novel repository for functional research. Blood 11 4, e10-e19 (2009).
-
(2009)
Blood
, vol.11
, Issue.4
-
-
Lewandrowski, U.1
-
139
-
-
58249142988
-
Methods for the measurement of platelet function
-
Michelson, A. D. Methods for the measurement of platelet function. Am. J. Cardiol. 103 (suppl. 3), 20A-6A (2009).
-
(2009)
Am. J. Cardiol.
, vol.103
, Issue.SUPPL. 3
-
-
Michelson, A.D.1
-
140
-
-
84884782037
-
-
2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
-
Steinhubl, S. R. in Platelets 2nd edn (ed. Michelson, A. D.) 509-518 (Elsevier/Academic Press, San Diego, 2007).
-
(2007)
Platelets
, pp. 509-518
-
-
Steinhubl, S.R.1
-
141
-
-
18244414272
-
Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists
-
Michelson, A. D. et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 101, 1013-1018 (2000).
-
(2000)
Circulation
, vol.101
, pp. 1013-1018
-
-
Michelson, A.D.1
-
142
-
-
36348943475
-
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
-
Brandt, J. T. et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost. 5, 2429-2436 (2007).
-
(2007)
J. Thromb. Haemost.
, vol.5
, pp. 2429-2436
-
-
Brandt, J.T.1
-
143
-
-
66349133650
-
Cytochrome P450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes
-
Mega, J. L. et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 11 9, 2553-2560 (2009).
-
(2009)
Circulation
, vol.11
, Issue.9
, pp. 2553-2560
-
-
Mega, J.L.1
-
144
-
-
58149476444
-
Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis
-
Bonello, L. et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am. J. Cardiol. 103, 5-10 (2009).
-
(2009)
Am. J. Cardiol.
, vol.103
, pp. 5-10
-
-
Bonello, L.1
-
145
-
-
57549099501
-
Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders
-
Cuisset, T. et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders. J. Am. Coll. Cardiol. Cardiovasc. Inter. 1, 649-653 (2008).
-
(2008)
J. Am. Coll. Cardiol. Cardiovasc. Inter.
, vol.1
, pp. 649-653
-
-
Cuisset, T.1
-
146
-
-
67650745975
-
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention Results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/ or resistance to clopidogrel study
-
Valgimigli, M. et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention. Results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/ or resistance to clopidogrel study. Circulation 11 9, 3215-3222 (2009).
-
(2009)
Circulation
, vol.11
, Issue.9
, pp. 3215-3222
-
-
Valgimigli, M.1
-
147
-
-
84884800657
-
-
2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
-
Andrews, R. K., Berndt, M. C. & Lopez, J. A. in Platelets 2nd edn (ed. Michelson, A. D.) 145-163 (Elsevier/Academic Press, San Diego, 2007).
-
(2007)
Platelets
, pp. 145-163
-
-
Andrews, R.K.1
Berndt, M.C.2
Lopez, J.A.3
-
148
-
-
73149093011
-
-
2nd edn (ed. Michelson, A. D.) Elsevier/ Academic Press, San Diego
-
Plow, E. F., Pesho, M. M. & Ma, Y. Q. in Platelets 2nd edn (ed. Michelson, A. D.) 165-178 (Elsevier/ Academic Press, San Diego, 2007).
-
(2007)
Platelets
, pp. 165-178
-
-
Plow, E.F.1
Pesho, M.M.2
Ma, Y.Q.3
-
151
-
-
50449098285
-
Mechanisms of thrombus formation
-
Furie, B. & Furie, B. C. Mechanisms of thrombus formation. N. Engl. J. Med. 359, 938-949 (2008).
-
(2008)
N. Engl. J. Med.
, vol.359
, pp. 938-949
-
-
Furie, B.1
Furie, B.C.2
-
152
-
-
34547760330
-
A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease
-
Lordkipanidze, M. et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur. Heart J. 28,1702-1708 (2007).
-
(2007)
Eur. Heart J.
, vol.28
, pp. 1702-1708
-
-
Lordkipanidze, M.1
|